| World Health Organization classification of tumours of haematopoietic and lymphoid tissues SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, ... Lyon: IARC press, 2008 | 2279 | 2008 |
| CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients CJ Turtle, LA Hanafi, C Berger, TA Gooley, S Cherian, M Hudecek, ... The Journal of clinical investigation 126 (6), 2123-2138, 2016 | 2075 | 2016 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 1644 | 2022 |
| Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells CJ Turtle, LA Hanafi, C Berger, M Hudecek, B Pender, E Robinson, ... Science translational medicine 8 (355), 355ra116-355ra116, 2016 | 1017 | 2016 |
| Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy KA Hay, LA Hanafi, D Li, J Gust, WC Liles, MM Wurfel, JA López, J Chen, ... Blood, The Journal of the American Society of Hematology 130 (21), 2295-2306, 2017 | 941 | 2017 |
| Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, ... Journal of Clinical Oncology 35 (26), 3010, 2017 | 675 | 2017 |
| Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy JA Hill, D Li, KA Hay, ML Green, S Cherian, X Chen, SR Riddell, ... Blood, The Journal of the American Society of Hematology 131 (1), 121-130, 2018 | 456 | 2018 |
| Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, ... Blood, The Journal of the American Society of Hematology 133 (15), 1652-1663, 2019 | 334 | 2019 |
| Ubiquitin-independent degradation of cell-cycle inhibitors by the REGγ proteasome X Chen, LF Barton, Y Chi, BE Clurman, JM Roberts Molecular cell 26 (6), 843-852, 2007 | 319 | 2007 |
| The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, ... Blood, The Journal of the American Society of Hematology 133 (17), 1876-1887, 2019 | 280 | 2019 |
| Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia X Chen, H Xie, BL Wood, RB Walter, JM Pagel, PS Becker, VK Sandhu, ... J Clin Oncol 33 (11), 1258-1264, 2015 | 269 | 2015 |
| A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression A Besson, M Gurian-West, X Chen, KS Kelly-Spratt, CJ Kemp, JM Roberts Genes & development 20 (1), 47-64, 2006 | 268 | 2006 |
| Multipotency of purified, transplanted globose basal cells in olfactory epithelium X Chen, H Fang, JE Schwob Journal of Comparative Neurology 469 (4), 457-474, 2004 | 247 | 2004 |
| N-acetylation and ubiquitin-independent proteasomal degradation of p21Cip1 X Chen, Y Chi, A Bloecher, R Aebersold, BE Clurman, JM Roberts Molecular cell 16 (5), 839-847, 2004 | 160 | 2004 |
| Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature TK Roberts, X Chen, JJ Liao Experimental Hematology & Oncology 5, 1-14, 2015 | 119 | 2015 |
| Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities X Chen, BL Wood Blood reviews 31 (2), 63-75, 2017 | 94 | 2017 |
| Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy M Shadman, J Gauthier, KA Hay, JM Voutsinas, F Milano, A Li, ... Blood advances 3 (20), 3062-3069, 2019 | 87 | 2019 |
| Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer I Timmerbeul, CM Garrett-Engele, U Kossatz, X Chen, E Firpo, ... Proceedings of the National Academy of Sciences 103 (38), 14009-14014, 2006 | 87 | 2006 |
| Anti-CD19 chimeric antigen receptor-modified T Cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion … CJ Turtle, C Berger, D Sommermeyer, LA Hanafi, B Pender, EM Robinson, ... Blood 126 (23), 184, 2015 | 84 | 2015 |
| Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B … CJ Turtle, LA Hanafi, C Berger, D Sommermeyer, B Pender, EM Robinson, ... Blood 126 (23), 3773, 2015 | 58 | 2015 |
